Alzheimer's Drug Cuts Hallmark Inflammation Related to Metabolic Syndrome 25 Percent

An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the United States, according to new clinical trial results by scientists at Northwell Health's Feinstein Institute for Medical Research.

In a study released today in JCI Insight, Feinstein Institute researchers found that the FDA-approved Alzheimer's drug "galantamine" cut key markers of inflammation – a hallmark of metabolic syndrome – by more than 25 percent, leading to reduced insulin resistance. A cluster of four risk factors — increased blood pressure, a high blood sugar level, excess body fat around the waist and abnormal cholesterol levels — comprise metabolic syndrome, which greatly raises risks for cardiovascular disease and type 2 diabetes.

But there is no treatment for metabolic syndrome as a whole, leaving physicians to tackle the condition by treating symptoms. From previous studies at the Feinstein Institute, Associate Professor Valentin A. Pavlov, PhD, and his colleagues knew that galantamine – derived synthetically from flowers used in Greek mythology to combat memory loss and delirium – lessened inflammation levels in mice with obesity. Since inflammation plays a key role in metabolic syndrome, they decided to study the effect of galantamine in people with the condition. 

"It's been very tough to come up with a treatment that targets all the components of metabolic syndrome, which is becoming a pandemic because it stems from obesity," said Dr. Pavlov, corresponding author of the new research. "By repurposing galantamine, it means we don't have to start from zero to establish its safety. We already know it's safe."

"Galantamine can target the entire syndrome as well as targeting components of the syndrome," said study co-author Yael Tobi Harris, MD, chief of endocrinology, diabetes and metabolism at North Shore University Hospital and Long Island Jewish Medical Center, part of Northwell Health. "Using an existing drug is a much faster way of getting a treatment out there. It's promising, it makes me optimistic, and it's a starting point indicating an avenue of research that should be pursued further."

Galantamine belongs to a class of drugs known as acetylcholinesterase inhibitors, which slow the breakdown of the neurotransmitter acetylcholine, a chemical messenger in the brain.

The Feinstein Investigators collaborated with a team of colleagues led by Dr. Fernanda Consolim-Colombo from the University of Sao Paulo, Brazil to perform a randomized, double-blinded, placebo-controlled clinical study of the effects of galantamine in patients with metabolic syndrome. In the study, 30 patients with metabolic syndrome received graduated doses of galantamine daily for 12 weeks and another group of 30 patients received a placebo during this same timeframe. Levels of inflammatory molecules indicating patients' metabolic syndrome-associated inflammation were tracked.

Also measured were participants' insulin levels, insulin resistance (HOMA-IR) heart rate and heart rate variability, and other metabolic and cardiovascular markers. At the end of the 12-week treatment period, those treated with galantamine experienced significantly reduced levels of pro-inflammatory molecules and higher levels of anti-inflammatory molecules compared to placebo patients. The galantamine group also experienced a significant decrease in insulin levels and insulin resistance compared with the placebo group.